Tarsus Pharmaceuticals, Inc. TARS Business Segments — Interest Expense, Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — interest expense, nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — interest expense, nonoperating?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — interest expense, nonoperating of $2.13M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — interest expense, nonoperating changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — interest expense, nonoperating decreased by 3.8% year-over-year, from $2.21M to $2.13M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — interest expense, nonoperating?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — interest expense, nonoperating has grown at a 59.6% compound annual growth rate (CAGR), from $2.2M to $8.94M.
- What does business segments — interest expense, nonoperating mean?
- This metric represents the costs incurred by the business segment related to debt financing and other non-operating financial obligations. It reflects the interest expense associated with capital structures that are not directly tied to core operational activities. Monitoring this helps investors understand the segment's reliance on external debt and the associated financial burden on its profitability.